Dapagliflozin vs janagliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Dapagliflozin · Farxiga / Forxiga

Marketed by AstraZeneca and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00528372 · Phase 3 · completed

The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) (met)

Result source: NCT01392677

janagliflozin · Huiyoujing

Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT03811548 · Phase 3 · status unknown

This randomised, double-blind, placebo-controlled Phase 3 trial randomised 432 drug-naive Chinese patients with type 2 diabetes 1:1:1 to placebo or janagliflozin 25 mg or 50 mg. The primary endpoint, HbA1c change at week 24, was met for both doses (placebo-adjusted -0.80% and -0.88%, P<0.001).

432 patients were randomised (publication); the registry's 442 is an estimate on a record not updated since 2020.

Next expected readout: December 2027 · NCT07244003 (registry estimate)

Reported efficacy

Change in HbA1c From Baseline to Week 24 (Baseline and Week 24): Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023) (met)

Result source: NCT03811548

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDapagliflozinjanagliflozin
HbA1c, change-0.9% vs -0.2%−0.7 vs placebo10 mg AM · wk 24 · n 65NCT00528372
50 other results
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 73 · Phase 3 · primary NCT00528372
  • -0.9% vs -0.2% 10 mg · wk 24 · n 108 · Phase 3 · primary NCT01392677
  • -0.9% vs -0.3% 10mg · wk 24 · n 192 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 5mg · wk 24 · n 210 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 2.5mg · wk 24 · n 198 · Phase 3 · primary NCT00673231
  • -0.6% vs 0.1% 10 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.7% vs 0.1% 20 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.8% vs -0.2% 5 mg AM · wk 24 · n 61 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 63 · Phase 3 · primary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 64 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 62 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.3% 10 mg · wk 24 · n 132 · Phase 3 · primary NCT00528879
  • -0.8% vs -0.1% 10 mg · wk 24 · n 150 · Phase 3 · primary NCT00680745
  • -1.0% vs -0.4% 10MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 5 mg · wk 24 · n 133 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 5 mg · wk 24 · n 142 · Phase 3 · primary NCT00680745
  • -0.8% vs -0.4% 5MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 135 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 2.5 mg · wk 24 · n 154 · Phase 3 · primary NCT00680745
  • -0.6% vs 0.4% wk 26 · n 75 · Phase 3 · primary NCT03199053
  • -0.5% vs 0.0% wk 24 · n 223 · Phase 3 · primary NCT00984867
  • -1.2% vs -1.4% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 185 · Phase 3 · primary NCT00643851
  • -0.5% vs -0.5% wk 52 · n 400 · Phase 3 · primary NCT00660907
  • -2.0% vs -1.4% wk 24 · n 202 · Phase 3 · primary NCT00859898
  • -1.4% vs -1.4% wk 24 · n 216 · Phase 3 · primary NCT00859898
  • -0.9% vs -0.2% 10 mg AM · wk 24 · n 59 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 60 · Phase 3 · secondary NCT00528372
  • -0.7% vs -0.2% 5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 48 · Phase 3 · secondary NCT00528372
  • -0.9% vs -0.3% 10 mg · wk 24 · n 104 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 118 · Phase 3 · secondary NCT00528879
  • -2.0% vs 0.2% 10 mg AM · wk 24 · n 14 · Phase 3 · secondary NCT00528372
  • -1.2% vs 0.2% 10 mg PM · wk 24 · n 12 · Phase 3 · secondary NCT00528372
  • -1.4% vs -0.5% 5 mg · wk 24 · n 34 · Phase 3 · secondary NCT00528879
  • -0.8% vs 0.0% wk 24 · n 94 · Phase 3 · secondary NCT00984867
  • -2% vs 0.2% 5 mg AM · wk 24 · n 9 · Phase 3 · secondary NCT00528372
  • -1.5% vs 0.2% 5 mg PM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.3% vs 0.2% 2.5 mg AM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.4% vs 0.2% 2.5 mg PM · wk 24 · n 11 · Phase 3 · secondary NCT00528372
  • -1.3% vs -0.5% 10 mg · wk 24 · n 18 · Phase 3 · secondary NCT00528879
  • -1.2% vs -0.5% 2.5 mg · wk 24 · n 17 · Phase 3 · secondary NCT00528879
  • -1.7% vs -1.8% 5 mg · wk 24 · n 96 · Phase 3 · secondary NCT00643851
  • -3.0% vs -1.8% wk 24 · n 92 · Phase 3 · secondary NCT00643851
  • -2.6% vs -2.0% wk 24 · n 106 · Phase 3 · secondary NCT00859898
  • -2.1% vs -2.0% wk 24 · n 97 · Phase 3 · secondary NCT00859898
  • -1% vs -0.5% wk 52 · n 56 · Phase 4 · secondary NCT02564926
—Not reported
Body weight, change (kg)-3.2 vs -2.2−1 vs placebo10 mg AM · wk 24 · n 69NCT00528372
40 other results
  • -3.0 vs -2.2 10 mg PM · wk 24 · n 74 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg AM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg PM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • -2.6 vs -0.6 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.7 vs 0.0 10mg · wk 24 · n 192 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 5mg · wk 24 · n 210 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 2.5mg · wk 24 · n 198 · Phase 3 · secondary NCT00673231
  • -2.8 vs -2.2 5 mg AM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • -3.5 vs -2.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -2.9 vs -2.4 5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -3.7 vs -2.4 5 mg PM · wk 24 · n 57 · Phase 3 · secondary NCT00528372
  • -3.3 vs -2.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -3.8 vs -2.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 2.5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -4.3 vs -2.4 2.5 mg PM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -2.9 vs -0.9 10 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • -3.1 vs -1.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT00528879
  • -2.3 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT00680745
  • -2.5 vs -0.8 10 mg · wk 24 · n 99 · Phase 3 · secondary NCT00680745
  • -0.1 vs 1.6 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.1 vs 1.8 10MG · wk 24 · n 113 · Phase 3 · secondary NCT00683878
  • -3.0 vs -0.9 5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -3.2 vs -1.0 5 mg · wk 24 · n 111 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.7 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.7 vs -0.8 5 mg · wk 24 · n 97 · Phase 3 · secondary NCT00680745
  • 0.1 vs 1.6 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 0.3 vs 1.8 5MG · wk 24 · n 101 · Phase 3 · secondary NCT00683878
  • -2.2 vs -0.9 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -2.4 vs -1.0 2.5 mg · wk 24 · n 120 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.7 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -1.2 vs -0.8 2.5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00680745
  • -2.1 vs -0.3 wk 24 · n 223 · Phase 3 · secondary NCT00984867
  • -2.6 vs -1.3 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -2.9 vs -1.5 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT00643851
  • -2.7 vs -1.3 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.0 vs -1.5 wk 24 · n 142 · Phase 3 · secondary NCT00643851
  • -3.2 vs 1.4 wk 52 · n 400 · Phase 3 · secondary NCT00660907
  • -3.3 vs -1.4 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.7 vs -1.4 wk 24 · n 219 · Phase 3 · secondary NCT00859898
  • -2.4 vs 1.3 wk 52 · n 56 · Phase 4 · secondary NCT02564926
—Not reported
HbA1c below 7%50.8% vs 31.6%+19.2 vs placebo10 mg AM · wk 24 · n 65NCT00528372
17 other results
  • 51.6% vs 31.6% 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • 31.8% vs 11.1% 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • 44.2% vs 31.6% 5 mg AM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • 44% vs 31.6% 5 mg PM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • 41.3% vs 31.6% 2.5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • 51.4% vs 31.6% 2.5 mg PM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • 40.6% vs 25.9% 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • 31.7% vs 13% 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • 38.8% vs 22.4% 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 37.5% vs 25.9% 5 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • 30.3% vs 13% 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • 32.5% vs 22.4% 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 33% vs 25.9% 2.5 mg · wk 24 · n 135 · Phase 3 · secondary NCT00528879
  • 26.8% vs 13% 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • 26.6% vs 10% wk 26 · n 64 · Phase 3 · secondary NCT03199053
  • 22.5% vs 34.6% 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT00643851
  • 52.4% vs 34.6% wk 24 · n 185 · Phase 3 · secondary NCT00643851
—Not reported
Fasting plasma glucose, change-1.3 vs 0.2−1.5 vs placebowk 24 · n 222NCT00984867
34 other results
  • -1.6 vs -0.2 10 mg AM · wk 24 · n 70 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.2 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • -1.9 vs -0.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.2 vs 0.2 10mg · wk 24 · n 183 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.2 5mg · wk 24 · n 204 · Phase 3 · secondary NCT00673231
  • 0.1 vs 1.0 10 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -0.9 vs -0.1 10 mg AM · wk 1 · n 65 · Phase 3 · secondary NCT00528372
  • -0.7 vs 0.2 2.5mg · wk 24 · n 190 · Phase 3 · secondary NCT00673231
  • -1.1 vs -0.1 10 mg PM · wk 1 · n 60 · Phase 3 · secondary NCT00528372
  • -0.5 vs 1.0 20 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -1.3 vs -0.2 5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • -1.5 vs -0.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -0.9 vs -0.1 5 mg AM · wk 1 · n 56 · Phase 3 · secondary NCT00528372
  • -1.0 vs -0.1 5 mg PM · wk 1 · n 54 · Phase 3 · secondary NCT00528372
  • -0.8 vs -0.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -1.4 vs -0.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -0.2 vs -0.1 2.5 mg AM · wk 1 · n 57 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.1 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • -0.8 vs -0.1 2.5 mg PM · wk 1 · n 48 · Phase 3 · secondary NCT00528372
  • -1.3 vs -0.3 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.3 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.9 vs 0.1 10 mg · wk 1 · n 115 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.3 5 mg · wk 24 · n 136 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.1 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.4 vs -0.3 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.7 vs 0.1 5 mg · wk 1 · n 121 · Phase 3 · secondary NCT00528879
  • -1.0 vs -0.3 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -0.9 vs -0.1 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -0.3 vs 0.1 2.5 mg · wk 1 · n 120 · Phase 3 · secondary NCT00528879
  • -0.6 vs 0.5 wk 26 · n 75 · Phase 3 · secondary NCT03199053
  • -2.3 vs -1.9 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.6 vs -1.9 wk 24 · n 216 · Phase 3 · secondary NCT00859898
—Not reported
3-point MACE (% with event)—Not posted · NCT04170998—Not reported

HbA1c, change

Dapagliflozin
-0.9% vs -0.2%−0.7 vs placebo10 mg AM · wk 24 · n 65NCT00528372
50 other results
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 73 · Phase 3 · primary NCT00528372
  • -0.9% vs -0.2% 10 mg · wk 24 · n 108 · Phase 3 · primary NCT01392677
  • -0.9% vs -0.3% 10mg · wk 24 · n 192 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 5mg · wk 24 · n 210 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 2.5mg · wk 24 · n 198 · Phase 3 · primary NCT00673231
  • -0.6% vs 0.1% 10 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.7% vs 0.1% 20 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.8% vs -0.2% 5 mg AM · wk 24 · n 61 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 63 · Phase 3 · primary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 64 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 62 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.3% 10 mg · wk 24 · n 132 · Phase 3 · primary NCT00528879
  • -0.8% vs -0.1% 10 mg · wk 24 · n 150 · Phase 3 · primary NCT00680745
  • -1.0% vs -0.4% 10MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 5 mg · wk 24 · n 133 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 5 mg · wk 24 · n 142 · Phase 3 · primary NCT00680745
  • -0.8% vs -0.4% 5MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 135 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 2.5 mg · wk 24 · n 154 · Phase 3 · primary NCT00680745
  • -0.6% vs 0.4% wk 26 · n 75 · Phase 3 · primary NCT03199053
  • -0.5% vs 0.0% wk 24 · n 223 · Phase 3 · primary NCT00984867
  • -1.2% vs -1.4% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 185 · Phase 3 · primary NCT00643851
  • -0.5% vs -0.5% wk 52 · n 400 · Phase 3 · primary NCT00660907
  • -2.0% vs -1.4% wk 24 · n 202 · Phase 3 · primary NCT00859898
  • -1.4% vs -1.4% wk 24 · n 216 · Phase 3 · primary NCT00859898
  • -0.9% vs -0.2% 10 mg AM · wk 24 · n 59 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 60 · Phase 3 · secondary NCT00528372
  • -0.7% vs -0.2% 5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 48 · Phase 3 · secondary NCT00528372
  • -0.9% vs -0.3% 10 mg · wk 24 · n 104 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 118 · Phase 3 · secondary NCT00528879
  • -2.0% vs 0.2% 10 mg AM · wk 24 · n 14 · Phase 3 · secondary NCT00528372
  • -1.2% vs 0.2% 10 mg PM · wk 24 · n 12 · Phase 3 · secondary NCT00528372
  • -1.4% vs -0.5% 5 mg · wk 24 · n 34 · Phase 3 · secondary NCT00528879
  • -0.8% vs 0.0% wk 24 · n 94 · Phase 3 · secondary NCT00984867
  • -2% vs 0.2% 5 mg AM · wk 24 · n 9 · Phase 3 · secondary NCT00528372
  • -1.5% vs 0.2% 5 mg PM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.3% vs 0.2% 2.5 mg AM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.4% vs 0.2% 2.5 mg PM · wk 24 · n 11 · Phase 3 · secondary NCT00528372
  • -1.3% vs -0.5% 10 mg · wk 24 · n 18 · Phase 3 · secondary NCT00528879
  • -1.2% vs -0.5% 2.5 mg · wk 24 · n 17 · Phase 3 · secondary NCT00528879
  • -1.7% vs -1.8% 5 mg · wk 24 · n 96 · Phase 3 · secondary NCT00643851
  • -3.0% vs -1.8% wk 24 · n 92 · Phase 3 · secondary NCT00643851
  • -2.6% vs -2.0% wk 24 · n 106 · Phase 3 · secondary NCT00859898
  • -2.1% vs -2.0% wk 24 · n 97 · Phase 3 · secondary NCT00859898
  • -1% vs -0.5% wk 52 · n 56 · Phase 4 · secondary NCT02564926
janagliflozin
—Not reported

Body weight, change (kg)

Dapagliflozin
-3.2 vs -2.2−1 vs placebo10 mg AM · wk 24 · n 69NCT00528372
40 other results
  • -3.0 vs -2.2 10 mg PM · wk 24 · n 74 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg AM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg PM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • -2.6 vs -0.6 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.7 vs 0.0 10mg · wk 24 · n 192 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 5mg · wk 24 · n 210 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 2.5mg · wk 24 · n 198 · Phase 3 · secondary NCT00673231
  • -2.8 vs -2.2 5 mg AM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • -3.5 vs -2.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -2.9 vs -2.4 5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -3.7 vs -2.4 5 mg PM · wk 24 · n 57 · Phase 3 · secondary NCT00528372
  • -3.3 vs -2.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -3.8 vs -2.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 2.5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -4.3 vs -2.4 2.5 mg PM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -2.9 vs -0.9 10 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • -3.1 vs -1.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT00528879
  • -2.3 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT00680745
  • -2.5 vs -0.8 10 mg · wk 24 · n 99 · Phase 3 · secondary NCT00680745
  • -0.1 vs 1.6 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.1 vs 1.8 10MG · wk 24 · n 113 · Phase 3 · secondary NCT00683878
  • -3.0 vs -0.9 5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -3.2 vs -1.0 5 mg · wk 24 · n 111 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.7 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.7 vs -0.8 5 mg · wk 24 · n 97 · Phase 3 · secondary NCT00680745
  • 0.1 vs 1.6 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 0.3 vs 1.8 5MG · wk 24 · n 101 · Phase 3 · secondary NCT00683878
  • -2.2 vs -0.9 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -2.4 vs -1.0 2.5 mg · wk 24 · n 120 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.7 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -1.2 vs -0.8 2.5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00680745
  • -2.1 vs -0.3 wk 24 · n 223 · Phase 3 · secondary NCT00984867
  • -2.6 vs -1.3 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -2.9 vs -1.5 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT00643851
  • -2.7 vs -1.3 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.0 vs -1.5 wk 24 · n 142 · Phase 3 · secondary NCT00643851
  • -3.2 vs 1.4 wk 52 · n 400 · Phase 3 · secondary NCT00660907
  • -3.3 vs -1.4 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.7 vs -1.4 wk 24 · n 219 · Phase 3 · secondary NCT00859898
  • -2.4 vs 1.3 wk 52 · n 56 · Phase 4 · secondary NCT02564926
janagliflozin
—Not reported

HbA1c below 7%

Dapagliflozin
50.8% vs 31.6%+19.2 vs placebo10 mg AM · wk 24 · n 65NCT00528372
17 other results
  • 51.6% vs 31.6% 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • 31.8% vs 11.1% 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • 44.2% vs 31.6% 5 mg AM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • 44% vs 31.6% 5 mg PM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • 41.3% vs 31.6% 2.5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • 51.4% vs 31.6% 2.5 mg PM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • 40.6% vs 25.9% 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • 31.7% vs 13% 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • 38.8% vs 22.4% 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 37.5% vs 25.9% 5 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • 30.3% vs 13% 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • 32.5% vs 22.4% 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 33% vs 25.9% 2.5 mg · wk 24 · n 135 · Phase 3 · secondary NCT00528879
  • 26.8% vs 13% 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • 26.6% vs 10% wk 26 · n 64 · Phase 3 · secondary NCT03199053
  • 22.5% vs 34.6% 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT00643851
  • 52.4% vs 34.6% wk 24 · n 185 · Phase 3 · secondary NCT00643851
janagliflozin
—Not reported

Fasting plasma glucose, change

Dapagliflozin
-1.3 vs 0.2−1.5 vs placebowk 24 · n 222NCT00984867
34 other results
  • -1.6 vs -0.2 10 mg AM · wk 24 · n 70 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.2 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • -1.9 vs -0.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.2 vs 0.2 10mg · wk 24 · n 183 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.2 5mg · wk 24 · n 204 · Phase 3 · secondary NCT00673231
  • 0.1 vs 1.0 10 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -0.9 vs -0.1 10 mg AM · wk 1 · n 65 · Phase 3 · secondary NCT00528372
  • -0.7 vs 0.2 2.5mg · wk 24 · n 190 · Phase 3 · secondary NCT00673231
  • -1.1 vs -0.1 10 mg PM · wk 1 · n 60 · Phase 3 · secondary NCT00528372
  • -0.5 vs 1.0 20 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -1.3 vs -0.2 5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • -1.5 vs -0.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -0.9 vs -0.1 5 mg AM · wk 1 · n 56 · Phase 3 · secondary NCT00528372
  • -1.0 vs -0.1 5 mg PM · wk 1 · n 54 · Phase 3 · secondary NCT00528372
  • -0.8 vs -0.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -1.4 vs -0.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -0.2 vs -0.1 2.5 mg AM · wk 1 · n 57 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.1 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • -0.8 vs -0.1 2.5 mg PM · wk 1 · n 48 · Phase 3 · secondary NCT00528372
  • -1.3 vs -0.3 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.3 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.9 vs 0.1 10 mg · wk 1 · n 115 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.3 5 mg · wk 24 · n 136 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.1 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.4 vs -0.3 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.7 vs 0.1 5 mg · wk 1 · n 121 · Phase 3 · secondary NCT00528879
  • -1.0 vs -0.3 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -0.9 vs -0.1 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -0.3 vs 0.1 2.5 mg · wk 1 · n 120 · Phase 3 · secondary NCT00528879
  • -0.6 vs 0.5 wk 26 · n 75 · Phase 3 · secondary NCT03199053
  • -2.3 vs -1.9 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.6 vs -1.9 wk 24 · n 216 · Phase 3 · secondary NCT00859898
janagliflozin
—Not reported

3-point MACE (% with event)

Dapagliflozin
—Not posted · NCT04170998
janagliflozin
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

janagliflozin
Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023) NCT03811548 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dapagliflozin: 4 of 4 rows · janagliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapagliflozin
Dropout rate
18.6%10 mg AMa
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
14.5%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.8%10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
18.8%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
16.2%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.7%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
13.4%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
0%20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
14.2%Dapagliflozin
NCT00859898 · Phase 3
13.3%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
16.3%5 mg
NCT00643851 · Phase 3
8.8%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
11.9%10 mg
NCT00528879 · Phase 3 · combination
10.9%5 mg
NCT00528879 · Phase 3 · combination
—5.0 mg
NCT00528879 · Phase 3 · combination
12.4%2.5 mg
NCT00528879 · Phase 3 · combination
20.7%
NCT00660907 · Phase 3 · combination
6.6%10 mg
NCT00680745 · Phase 3 · combination
9%5 mg
NCT00680745 · Phase 3 · combination
9.1%2.5 mg
NCT00680745 · Phase 3 · combination
7.3%10 mg
NCT01392677 · Phase 3 · combination
10%10MG
NCT00683878 · Phase 3 · combination
11.3%5MG
NCT00683878 · Phase 3 · combination
7.6%
NCT00984867 · Phase 3
9.2%10mg
NCT00673231 · Phase 3
12.3%5mg
NCT00673231 · Phase 3
10.9%2.5mg
NCT00673231 · Phase 3
2.5%10mg QD
NCT02413398 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3 · combination
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
6.2%Dapagliflozin
NCT03199053 · Phase 3 · background therapy
1.3%10 mg
NCT01730534 · Phase 3
16.7%Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
16.7%Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
0%T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
0%Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
0%Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
12.9%
NCT03782259 · Phase 4 · registry result, not featured evidence
16%
NCT02235298 · Phase 4 · registry result, not featured evidence
—
NCT02796170 · Phase 4 · registry result, not featured evidence
—10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
—
NCT02973477 · Phase 4 · registry result, not featured evidence
7.4%10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
7.7%
NCT02433678 · Phase 4 · registry result, not featured evidence
0%10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
8.3%
NCT03074630 · Phase 4 · registry result, not featured evidence
13.3%
NCT02564926 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
8.6%10 mg AMa
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
3.9%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.1%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
4.4%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.1%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
—20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
4.1%Dapagliflozin
NCT00859898 · Phase 3
1.9%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
3%5 mg
NCT00643851 · Phase 3
1%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
3%10 mg
NCT00528879 · Phase 3 · combination
1.5%5 mg
NCT00528879 · Phase 3 · combination
—5.0 mg
NCT00528879 · Phase 3 · combination
2.9%2.5 mg
NCT00528879 · Phase 3 · combination
8.1%
NCT00660907 · Phase 3 · combination
2%10 mg
NCT00680745 · Phase 3 · combination
2.1%5 mg
NCT00680745 · Phase 3 · combination
3.2%2.5 mg
NCT00680745 · Phase 3 · combination
0.9%10 mg
NCT01392677 · Phase 3 · combination
2.1%10MG
NCT00683878 · Phase 3 · combination
2.1%5MG
NCT00683878 · Phase 3 · combination
3.1%
NCT00984867 · Phase 3
3.1%10mg
NCT00673231 · Phase 3
4.2%5mg
NCT00673231 · Phase 3
2.5%2.5mg
NCT00673231 · Phase 3
—10mg QD
NCT02413398 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3 · combination
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—Dapagliflozin
NCT03199053 · Phase 3 · background therapy
—10 mg
NCT01730534 · Phase 3
—Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
—Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
—Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
—T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
—Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
—Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
—
NCT03782259 · Phase 4 · registry result, not featured evidence
4%
NCT02235298 · Phase 4 · registry result, not featured evidence
—
NCT02796170 · Phase 4 · registry result, not featured evidence
—10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
—
NCT02973477 · Phase 4 · registry result, not featured evidence
—10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
—
NCT02433678 · Phase 4 · registry result, not featured evidence
—10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
—
NCT03074630 · Phase 4 · registry result, not featured evidence
—
NCT02564926 · Phase 4 · registry result, not featured evidence
Serious AEs
1.4%10 mg AMa
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
3.9%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
7.4%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.4%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
4.2%20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
2.3%Dapagliflozin
NCT00859898 · Phase 3
1.4%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
4.4%5 mg
NCT00643851 · Phase 3
3.1%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
10.4%10 mg
NCT00528879 · Phase 3 · combination
—5 mg
NCT00528879 · Phase 3 · combination
6.6%5.0 mg
NCT00528879 · Phase 3 · combination
10.9%2.5 mg
NCT00528879 · Phase 3 · combination
8.6%
NCT00660907 · Phase 3 · combination
6%10 mg
NCT00680745 · Phase 3 · combination
6.9%5 mg
NCT00680745 · Phase 3 · combination
7.1%2.5 mg
NCT00680745 · Phase 3 · combination
0.9%10 mg
NCT01392677 · Phase 3 · combination
1.4%10MG
NCT00683878 · Phase 3 · combination
2.8%5MG
NCT00683878 · Phase 3 · combination
4.4%
NCT00984867 · Phase 3
7.1%10mg
NCT00673231 · Phase 3
4.7%5mg
NCT00673231 · Phase 3
7.4%2.5mg
NCT00673231 · Phase 3
5.6%10mg QD
NCT02413398 · Phase 3
0%10 mg
NCT03199053 · Phase 3
4.8%10 mg
NCT03199053 · Phase 3
0%10 mg
NCT03199053 · Phase 3 · combination
1.2%5 mg
NCT03199053 · Phase 3
0%5 mg
NCT03199053 · Phase 3
9.1%5 mg
NCT03199053 · Phase 3
—Dapagliflozin
NCT03199053 · Phase 3 · background therapy
37.4%10 mg
NCT01730534 · Phase 3
0%Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
0%T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
0%Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
0%Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
—
NCT03782259 · Phase 4 · registry result, not featured evidence
0%
NCT02235298 · Phase 4 · registry result, not featured evidence
0%
NCT02796170 · Phase 4 · registry result, not featured evidence
0%10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
2.3%
NCT02973477 · Phase 4 · registry result, not featured evidence
0%10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
0%
NCT02433678 · Phase 4 · registry result, not featured evidence
0%10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
—
NCT03074630 · Phase 4 · registry result, not featured evidence
10%
NCT02564926 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
10 mg AMa
nasopharyngitis 14.3% (placebo 9.3%)
arthralgia 8.6% (placebo 4%)
headache 8.6% (placebo 12%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 42 more results
10 mg PM
headache 13.2% (placebo 12%)
upper respiratory tract infection 11.8% (placebo 5.3%)
back pain 9.2% (placebo 6.7%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg AM
pharyngitis 9.4% (placebo 8%)
arthralgia 7.8% (placebo 4%)
headache 7.8% (placebo 12%)
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
5 mg PM
headache 16.2% (placebo 12%)
nasopharyngitis 13.2% (placebo 9.3%)
arthralgia 11.8% (placebo 4%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg AM
nasopharyngitis 16.9% (placebo 9.3%)
influenza 10.8% (placebo 4%)
arthralgia 9.2% (placebo 4%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg PM
nasopharyngitis 16.4% (placebo 9.3%)
abdominal pain 9% (placebo 2.7%)
dizziness 9% (placebo 2.7%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
back pain 12.5% (placebo 8.7%)
headache 12.5% (placebo 8.7%)
fatigue 8.3% (placebo 0%)
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
20 mg
nausea 12.5% (placebo 4.3%)
pollakiuria 12.5% (placebo 17.4%)
vomiting 12.5% (placebo 0%)
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
urinary tract infection 7.8%
vulvovaginal mycotic infection 5%
diarrhoea 2.7%
NCT00859898 · Phase 3
diarrhoea 7.1%
vulvovaginal mycotic infection 3.3%
urinary tract infection 2.8%
NCT00859898 · Phase 3 · combination
5 mg
dyslipidaemia 5.4%
upper respiratory tract infection 4.9%
urinary tract infection 4.4%
NCT00643851 · Phase 3
diarrhoea 7.7%
nausea 5.7%
upper respiratory tract infection 5.2%
NCT00643851 · Phase 3 · combination
10 mg
back pain 13.3% (placebo 8%)
influenza 12.6% (placebo 10.9%)
diarrhoea 11.9% (placebo 7.3%)
NCT00528879 · Phase 3 · combination
5.0 mg
influenza 14.6% (placebo 10.9%)
headache 9.5% (placebo 5.8%)
arthralgia 7.3% (placebo 5.1%)
NCT00528879 · Phase 3 · combination
2.5 mg
influenza 13.9% (placebo 10.9%)
nasopharyngitis 11.7% (placebo 8.8%)
back pain 8% (placebo 8%)
NCT00528879 · Phase 3 · combination
nasopharyngitis 10.6%
hypertension 7.4%
influenza 7.4%
NCT00660907 · Phase 3 · combination
10 mg
hypoglycemia 7.9% (placebo 4.8%)
nasopharyngitis 3.3% (placebo 2.7%)
hypertension 1.3% (placebo 4.1%)
NCT00680745 · Phase 3 · combination
5 mg
hypoglycemia 6.9% (placebo 4.8%)
nasopharyngitis 5.5% (placebo 2.7%)
hypertension 1.4% (placebo 4.1%)
NCT00680745 · Phase 3 · combination
2.5 mg
hypoglycemia 7.1% (placebo 4.8%)
hypertension 5.2% (placebo 4.1%)
nasopharyngitis 1.9% (placebo 2.7%)
NCT00680745 · Phase 3 · combination
10 mg
urinary tract infection 4.6% (placebo 6.4%)
NCT01392677 · Phase 3 · combination
10MG
dyslipidaemia 9.3% (placebo 4.3%)
nasopharyngitis 7.9% (placebo 3.6%)
diarrhoea 6.4% (placebo 4.3%)
NCT00683878 · Phase 3 · combination
5MG
upper respiratory tract infection 6.4% (placebo 5.8%)
dyslipidaemia 5.7% (placebo 4.3%)
nasopharyngitis 5% (placebo 3.6%)
NCT00683878 · Phase 3 · combination
nasopharyngitis 4% (placebo 6.2%)
NCT00984867 · Phase 3
10mg
hypoglycemia 44.9% (placebo 42.1%)
nasopharyngitis 8.7% (placebo 11.2%)
urinary tract infection 5.6% (placebo 3%)
NCT00673231 · Phase 3
5mg
hypoglycemia 47.6% (placebo 42.1%)
nasopharyngitis 13.7% (placebo 11.2%)
hypertension 6.1% (placebo 8.1%)
NCT00673231 · Phase 3
2.5mg
hypoglycemia 55% (placebo 42.1%)
nasopharyngitis 13.9% (placebo 11.2%)
hypertension 5.4% (placebo 8.1%)
NCT00673231 · Phase 3
10 mg
abdominal pain 4.8% (placebo 2.6%)
abdominal pain upper 4.8% (placebo 0%)
bronchitis 4.8% (placebo 0%)
NCT03199053 · Phase 3
10 mg
dysmenorrhoea 9.5% (placebo 2.6%)
headache 9.5% (placebo 1.3%)
conjunctivitis allergic 4.8% (placebo 0%)
NCT03199053 · Phase 3
10 mg
pharyngotonsillitis 14.3% (placebo 1.3%)
tonsillitis 14.3% (placebo 0%)
abdominal pain 0% (placebo 2.6%)
NCT03199053 · Phase 3 · combination
5 mg
headache 7.4% (placebo 1.3%)
hypertriglyceridaemia 4.9% (placebo 1.3%)
diarrhoea 3.7% (placebo 3.9%)
NCT03199053 · Phase 3
5 mg
headache 9.1% (placebo 1.3%)
nasopharyngitis 3.6% (placebo 2.6%)
anxiety 1.8% (placebo 0%)
NCT03199053 · Phase 3
5 mg
influenza 5.5% (placebo 2.6%)
abdominal pain upper 3.6% (placebo 0%)
headache 3.6% (placebo 1.3%)
NCT03199053 · Phase 3
10 mg
renal impairment 1.4% (placebo 1.7%)
acute kidney injury 1% (placebo 1.3%)
chronic kidney disease 0.9% (placebo 1.2%)
NCT01730534 · Phase 3
genital mycotic infection 13.3%
mild hypoglycemia 0%
NCT02911792 · Phase 4 · registry result, not featured evidence
genital mycotic infection 26.7%
mild hypoglycemia 0%
NCT02911792 · Phase 4 · registry result, not featured evidence
transcient syncope 12.5% (placebo 0%)
NCT02981966 · Phase 4 · registry result, not featured evidence
transcient syncope 0% (placebo 0%)
NCT02981966 · Phase 4 · registry result, not featured evidence
nausea and vomiting 24% (placebo 0%)
genital mycosis 0% (placebo 0%)
NCT02981069 · Phase 4 · registry result, not featured evidence
nausea and vomiting 20% (placebo 0%)
genital mycosis 8% (placebo 0%)
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
dysuria 12% (placebo 0%)
frequency of urination 12% (placebo 0%)
balanitis 2% (placebo 0%)
NCT02235298 · Phase 4 · registry result, not featured evidence
cold like symptoms 4.5%
genital yeast infection 4.5%
abrasion of left cornea 2.3%
NCT02973477 · Phase 4 · registry result, not featured evidence
10mg Once Daily
genital fungal infections 20.8%
NCT02682563 · Phase 4 · registry result, not featured evidence
nasopharyngitis 6.7%
toothache 6.7%
hypoglycaemia 5%
NCT02564926 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapagliflozin

HbA1c -0.89% (n=65) vs -0.23% (n=72) placebo @ 24wk10 mg AM
absolute change · percentage points
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 50 more results
-0.79% (n=73) vs -0.23% (n=72) placebo @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.04% (n=14) vs 0.19% (n=5) placebo @ 24wk10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.21% (n=12) vs 0.19% (n=5) placebo @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.88% (n=59) vs -0.21% (n=58) placebo @ 24wk10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.8% (n=60) vs -0.21% (n=58) placebo @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.61% (n=23) vs 0.09% (n=19) placebo @ 12wk10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
-0.86% (n=108) vs -0.17% (n=108) placebo @ 24wk10 mg
NCT01392677 · Phase 3 · combination
-0.9% (n=192) vs -0.3% (n=188) placebo @ 24wk10mg
NCT00673231 · Phase 3
-0.69% (n=23) vs 0.09% (n=19) placebo @ 12wk20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
-0.77% (n=61) vs -0.23% (n=72) placebo @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
-0.79% (n=63) vs -0.23% (n=72) placebo @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2% (n=9) vs 0.19% (n=5) placebo @ 24wk5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.53% (n=8) vs 0.19% (n=5) placebo @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.73% (n=53) vs -0.21% (n=58) placebo @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
-0.76% (n=54) vs -0.21% (n=58) placebo @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.19% (n=196) vs -1.35% (n=195) Metformin XR @ 24wk5 mg
NCT00643851 · Phase 3
-1.67% (n=96) vs -1.82% (n=101) Metformin XR @ 24wk5 mg
NCT00643851 · Phase 3
-0.82% (n=210) vs -0.3% (n=188) placebo @ 24wk5mg
NCT00673231 · Phase 3
-0.58% (n=64) vs -0.23% (n=72) placebo @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.83% (n=62) vs -0.23% (n=72) placebo @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.26% (n=8) vs 0.19% (n=5) placebo @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.35% (n=11) vs 0.19% (n=5) placebo @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.58% (n=53) vs -0.21% (n=58) placebo @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.81% (n=48) vs -0.21% (n=58) placebo @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.75% (n=198) vs -0.3% (n=188) placebo @ 24wk2.5mg
NCT00673231 · Phase 3
-0.84% (n=132) vs -0.3% (n=134) placebo @ 24wk10 mg
NCT00528879 · Phase 3 · combination
-1.32% (n=18) vs -0.53% (n=22) placebo @ 24wk10 mg
NCT00528879 · Phase 3 · combination
-0.88% (n=104) vs -0.31% (n=113) placebo @ 24wk10 mg
NCT00528879 · Phase 3 · combination
-0.82% (n=150) vs -0.13% (n=143) placebo @ 24wk10 mg
NCT00680745 · Phase 3 · combination
-0.97% (n=140) vs -0.42% (n=138) placebo @ 24wk10MG
NCT00683878 · Phase 3 · combination
-2.05% (n=185) vs -1.35% (n=195) Metformin XR @ 24wk
NCT00643851 · Phase 3 · combination
-3.01% (n=92) vs -1.82% (n=101) Metformin XR @ 24wk
NCT00643851 · Phase 3 · combination
-0.7% (n=133) vs -0.3% (n=134) placebo @ 24wk5 mg
NCT00528879 · Phase 3 · combination
-1.37% (n=34) vs -0.53% (n=22) placebo @ 24wk5 mg
NCT00528879 · Phase 3 · combination
-0.71% (n=109) vs -0.31% (n=113) placebo @ 24wk5 mg
NCT00528879 · Phase 3 · combination
-0.63% (n=142) vs -0.13% (n=143) placebo @ 24wk5 mg
NCT00680745 · Phase 3 · combination
-0.82% (n=140) vs -0.42% (n=138) placebo @ 24wk5MG
NCT00683878 · Phase 3 · combination
-0.67% (n=135) vs -0.3% (n=134) placebo @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
-1.21% (n=17) vs -0.53% (n=22) placebo @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
-0.69% (n=118) vs -0.31% (n=113) placebo @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
-0.58% (n=154) vs -0.13% (n=143) placebo @ 24wk2.5 mg
NCT00680745 · Phase 3 · combination
-1.98% (n=202) vs -1.44% (n=203) Metformin XR @ 24wk
NCT00859898 · Phase 3 · combination
-1.45% (n=216) vs -1.44% (n=203) Metformin XR @ 24wk
NCT00859898 · Phase 3
-2.59% (n=106) vs -2.05% (n=95) Metformin XR @ 24wk
NCT00859898 · Phase 3 · combination
-2.14% (n=97) vs -2.05% (n=95) Metformin XR @ 24wk
NCT00859898 · Phase 3
-0.52% (n=400) vs -0.52% (n=401) Glipizide Plus Metformin @ 52wk
NCT00660907 · Phase 3 · combination
-0.45% (n=223) vs 0.04% (n=223) placebo @ 24wk
NCT00984867 · Phase 3
-0.8% (n=94) vs 0.03% (n=99) placebo @ 24wk
NCT00984867 · Phase 3
-0.62% (n=75) vs 0.41% (n=70) placebo @ 26wk
NCT03199053 · Phase 3 · background therapy
-1% (n=56) vs -0.54% (n=56) Glimepiride @ 52wk
NCT02564926 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose -1.6 vs -0.23 placebo mmol/L @ 24wk10 mg AM
absolute change · mmol/L
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -28.8 mg/dL as posted
show 34 more results
-1.64 vs -0.23 placebo mmol/L @ 24wk*10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -29.6 mg/dL as posted
-0.89 vs -0.13 placebo mmol/L @ 1wk*10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -16.1 mg/dL as posted
-1.13 vs -0.13 placebo mmol/L @ 1wk*10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -20.3 mg/dL as posted
0.13 vs 0.99 placebo mmol/L @ 12wk*10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to mmol/L from 2.36 mg/dL as posted
-1.9 vs -0.04 placebo mmol/L @ 24wk*10 mg
NCT01392677 · Phase 3 · combination · converted to mmol/L from -34.23 mg/dL as posted
-1.2 vs 0.18 placebo mmol/L @ 24wk*10mg
NCT00673231 · Phase 3 · converted to mmol/L from -21.7 mg/dL as posted
-0.54 vs 0.99 placebo mmol/L @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to mmol/L from -9.64 mg/dL as posted
-1.34 vs -0.23 placebo mmol/L @ 24wk*5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -24.1 mg/dL as posted
-1.52 vs -0.23 placebo mmol/L @ 24wk*5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -27.3 mg/dL as posted
-0.91 vs -0.13 placebo mmol/L @ 1wk*5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -16.4 mg/dL as posted
-1.03 vs -0.13 placebo mmol/L @ 1wk*5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -18.6 mg/dL as posted
-2.33 vs -1.87 Metformin XR mmol/L @ 24wk*5 mg
NCT00643851 · Phase 3 · converted to mmol/L from -42 mg/dL as posted
-1.04 vs 0.18 placebo mmol/L @ 24wk*5mg
NCT00673231 · Phase 3 · converted to mmol/L from -18.8 mg/dL as posted
-0.84 vs -0.23 placebo mmol/L @ 24wk*2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -15.2 mg/dL as posted
-1.42 vs -0.23 placebo mmol/L @ 24wk*2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -25.6 mg/dL as posted
-0.16 vs -0.13 placebo mmol/L @ 1wk*2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -2.9 mg/dL as posted
-0.8 vs -0.13 placebo mmol/L @ 1wk*2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.4 mg/dL as posted
-0.69 vs 0.18 placebo mmol/L @ 24wk*2.5mg
NCT00673231 · Phase 3 · converted to mmol/L from -12.5 mg/dL as posted
-1.3 vs -0.33 placebo mmol/L @ 24wk*10 mg
NCT00528879 · Phase 3 · combination · converted to mmol/L from -23.5 mg/dL as posted
-0.92 vs 0.07 placebo mmol/L @ 1wk*10 mg
NCT00528879 · Phase 3 · combination · converted to mmol/L from -16.5 mg/dL as posted
-1.58 vs -0.11 placebo mmol/L @ 24wk*10 mg
NCT00680745 · Phase 3 · combination · converted to mmol/L from -28.5 mg/dL as posted
-1.64 vs -0.31 placebo mmol/L @ 24wk*10MG
NCT00683878 · Phase 3 · combination · converted to mmol/L from -29.6 mg/dL as posted
-3.39 vs -1.87 Metformin XR mmol/L @ 24wk*
NCT00643851 · Phase 3 · combination · converted to mmol/L from -61 mg/dL as posted
-1.19 vs -0.33 placebo mmol/L @ 24wk*5 mg
NCT00528879 · Phase 3 · combination · converted to mmol/L from -21.5 mg/dL as posted
-0.67 vs 0.07 placebo mmol/L @ 1wk*5 mg
NCT00528879 · Phase 3 · combination · converted to mmol/L from -12 mg/dL as posted
-1.18 vs -0.11 placebo mmol/L @ 24wk*5 mg
NCT00680745 · Phase 3 · combination · converted to mmol/L from -21.2 mg/dL as posted
-1.38 vs -0.31 placebo mmol/L @ 24wk*5MG
NCT00683878 · Phase 3 · combination · converted to mmol/L from -24.9 mg/dL as posted
-0.99 vs -0.33 placebo mmol/L @ 24wk*2.5 mg
NCT00528879 · Phase 3 · combination · converted to mmol/L from -17.8 mg/dL as posted
-0.33 vs 0.07 placebo mmol/L @ 1wk*2.5 mg
NCT00528879 · Phase 3 · combination · converted to mmol/L from -6 mg/dL as posted
-0.93 vs -0.11 placebo mmol/L @ 24wk*2.5 mg
NCT00680745 · Phase 3 · combination · converted to mmol/L from -16.8 mg/dL as posted
-3.35 vs -1.93 Metformin XR mmol/L @ 24wk*
NCT00859898 · Phase 3 · combination · converted to mmol/L from -60.4 mg/dL as posted
-2.58 vs -1.93 Metformin XR mmol/L @ 24wk*
NCT00859898 · Phase 3 · converted to mmol/L from -46.4 mg/dL as posted
-1.34 vs 0.21 placebo mmol/L @ 24wk*
NCT00984867 · Phase 3 · converted to mmol/L from -24.11 mg/dL as posted
-0.57 vs 0.51 placebo mmol/L @ 26wk
NCT03199053 · Phase 3 · background therapy
Fasting Plasma Glucose -4.68 mmol/L @ 24wk10 mg AM
absolute change · mmol/L
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -84.3 mg/dL as posted
show 5 more results
-4.12 mmol/L @ 1wk*10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -74.3 mg/dL as posted
-1.62 mmol/L @ 26wk10 mg
NCT03199053 · Phase 3
-4.27 mmol/L @ 24wk*5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -77 mg/dL as posted
-3.01 mmol/L @ 1wk*5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -54.3 mg/dL as posted
-0.98 mmol/L @ 26wk5 mg
NCT03199053 · Phase 3
Weight -3.16 vs -2.19 placebo kg @ 24wk10 mg AM
absolute change · kg
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 40 more results
-3.05 vs -2.19 placebo kg @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-3.39 vs -2.43 placebo kg @ 24wk10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-3.39 vs -2.43 placebo kg @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.65 vs -0.58 placebo kg @ 24wk10 mg
NCT01392677 · Phase 3 · combination
-1.67 vs 0.02 placebo kg @ 24wk10mg
NCT00673231 · Phase 3
-2.83 vs -2.19 placebo kg @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
-3.55 vs -2.19 placebo kg @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.91 vs -2.43 placebo kg @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
-3.7 vs -2.43 placebo kg @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.61 vs -1.29 Metformin XR kg @ 24wk5 mg
NCT00643851 · Phase 3
-2.88 vs -1.47 Metformin XR kg @ 24wk5 mg
NCT00643851 · Phase 3
-0.98 vs 0.02 placebo kg @ 24wk5mg
NCT00673231 · Phase 3
-3.25 vs -2.19 placebo kg @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-3.82 vs -2.19 placebo kg @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-3.43 vs -2.43 placebo kg @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-4.3 vs -2.43 placebo kg @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.98 vs 0.02 placebo kg @ 24wk2.5mg
NCT00673231 · Phase 3
-2.86 vs -0.89 placebo kg @ 24wk10 mg
NCT00528879 · Phase 3 · combination
-3.09 vs -1.01 placebo kg @ 24wk10 mg
NCT00528879 · Phase 3 · combination
-2.26 vs -0.72 placebo kg @ 24wk10 mg
NCT00680745 · Phase 3 · combination
-2.47 vs -0.8 placebo kg @ 24wk10 mg
NCT00680745 · Phase 3 · combination
-0.14 vs 1.64 placebo kg @ 24wk10MG
NCT00683878 · Phase 3 · combination
-0.07 vs 1.83 placebo kg @ 24wk10MG
NCT00683878 · Phase 3 · combination
-2.66 vs -1.29 Metformin XR kg @ 24wk
NCT00643851 · Phase 3 · combination
-3.04 vs -1.47 Metformin XR kg @ 24wk
NCT00643851 · Phase 3 · combination
-3.04 vs -0.89 placebo kg @ 24wk5 mg
NCT00528879 · Phase 3 · combination
-3.21 vs -1.01 placebo kg @ 24wk5 mg
NCT00528879 · Phase 3 · combination
-1.56 vs -0.72 placebo kg @ 24wk5 mg
NCT00680745 · Phase 3 · combination
-1.74 vs -0.8 placebo kg @ 24wk5 mg
NCT00680745 · Phase 3 · combination
0.09 vs 1.64 placebo kg @ 24wk5MG
NCT00683878 · Phase 3 · combination
0.26 vs 1.83 placebo kg @ 24wk5MG
NCT00683878 · Phase 3 · combination
-2.21 vs -0.89 placebo kg @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
-2.39 vs -1.01 placebo kg @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
-1.18 vs -0.72 placebo kg @ 24wk2.5 mg
NCT00680745 · Phase 3 · combination
-1.17 vs -0.8 placebo kg @ 24wk2.5 mg
NCT00680745 · Phase 3 · combination
-3.33 vs -1.36 Metformin XR kg @ 24wk
NCT00859898 · Phase 3 · combination
-2.73 vs -1.36 Metformin XR kg @ 24wk
NCT00859898 · Phase 3
-3.22 vs 1.44 Glipizide Plus Metformin kg @ 52wk
NCT00660907 · Phase 3 · combination
-2.14 vs -0.26 placebo kg @ 24wk
NCT00984867 · Phase 3
-2.4 vs 1.3 Glimepiride kg @ 52wk
NCT02564926 · Phase 4 · registry result, not featured evidence
Weight -1.9 kg @ 24wk10 mg AM
absolute change · kg
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
-2.06 kg @ 24wk5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 50.8% (n=65) vs 31.6% (n=72) placebo @ 24wk10 mg AM
responder rate · % of participants
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 17 more results
51.6% (n=73) vs 31.6% (n=72) placebo @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
31.8% (n=108) vs 11.1% (n=108) placebo @ 24wk10 mg
NCT01392677 · Phase 3 · combination
44.2% (n=61) vs 31.6% (n=72) placebo @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
44% (n=63) vs 31.6% (n=72) placebo @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.5% (n=196) vs 34.6% (n=195) Metformin XR @ 24wk5 mg
NCT00643851 · Phase 3
41.3% (n=64) vs 31.6% (n=72) placebo @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
51.4% (n=62) vs 31.6% (n=72) placebo @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
40.6% (n=132) vs 25.9% (n=134) placebo @ 24wk10 mg
NCT00528879 · Phase 3 · combination
31.7% (n=150) vs 13% (n=143) placebo @ 24wk10 mg
NCT00680745 · Phase 3 · combination
38.8% (n=140) vs 22.4% (n=138) placebo @ 24wk10MG
NCT00683878 · Phase 3 · combination
52.4% (n=185) vs 34.6% (n=195) Metformin XR @ 24wk
NCT00643851 · Phase 3 · combination
37.5% (n=133) vs 25.9% (n=134) placebo @ 24wk5 mg
NCT00528879 · Phase 3 · combination
30.3% (n=142) vs 13% (n=143) placebo @ 24wk5 mg
NCT00680745 · Phase 3 · combination
32.5% (n=140) vs 22.4% (n=138) placebo @ 24wk5MG
NCT00683878 · Phase 3 · combination
33% (n=135) vs 25.9% (n=134) placebo @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
26.8% (n=154) vs 13% (n=143) placebo @ 24wk2.5 mg
NCT00680745 · Phase 3 · combination
26.6% (n=64) vs 10% (n=50) placebo @ 26wk
NCT03199053 · Phase 3 · background therapy
HbA1c Less Than or Equal to 6.5 23.1% (n=14) vs 14.5% (n=11) placebo @ 24wk10 mg AM
responder rate · % of participants
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
26% (n=73) vs 14.5% (n=11) placebo @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
26.6% (n=17) vs 14.5% (n=11) placebo @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
25.8% (n=63) vs 14.5% (n=11) placebo @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
27.2% (n=17) vs 14.5% (n=11) placebo @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
33.4% (n=62) vs 14.5% (n=11) placebo @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
25.2% (n=36) vs 13.8% (n=18) placebo @ 24wk10 mg
NCT00528879 · Phase 3 · combination
14.5% (n=18) vs 13.8% (n=18) placebo @ 24wk5 mg
NCT00528879 · Phase 3 · combination
20.7% (n=29) vs 13.8% (n=18) placebo @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
HbA1c -2.66% (n=32) @ 24wk10 mg AM
absolute change · percentage points
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-0.74% (n=19) @ 26wk10 mg
NCT03199053 · Phase 3
-2.88% (n=25) @ 24wk5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.71% (n=21) @ 26wk5 mg
NCT03199053 · Phase 3
HbA1c 7.0 or Less 13% (n=23) vs 5.3% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 3 Participants as posted
show 1 more result
4.3% (n=23) vs 5.3% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted
HbA1c Less Than or Equal to 6.5 4.3% (n=23) vs 0% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted
show 1 more result
0% (n=23) vs 0% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 0 Participants as posted
HbA1C Decrease at Least 0.5 65.2% (n=23) vs 15.8% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 15 Participants as posted
show 1 more result
65.2% (n=23) vs 15.8% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 15 Participants as posted
TDDI Change Units Per -1.35 vs 1.69 placebo per day @ 12wk10 mg
absolute change · per day
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
show 4 more results
-1.16 vs 5.08 placebo per day @ 24wk10mg
NCT00673231 · Phase 3
-0.83 vs 1.69 placebo per day @ 12wk20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
-0.61 vs 5.08 placebo per day @ 24wk5mg
NCT00673231 · Phase 3
-1.8 vs 5.08 placebo per day @ 24wk2.5mg
NCT00673231 · Phase 3

+ 41 further endpoints in the CSV export.

Chronic Kidney Disease

Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline

Dapagliflozin · Farxiga / Forxiga

Marketed by AstraZeneca and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT03036150 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial measuring a hard clinical composite of kidney failure and death, and dapagliflozin significantly reduced this composite compared with placebo.

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death. (Up to 38.2 months): Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001 (met)

Result source: NCT03036150

janagliflozin · Huiyoujing

Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2031 · NCT07116928 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDapagliflozinjanagliflozin
Kidney composite outcome6.6% vs 11.3%−4.7 vs placebon 2152NCT03036150—Not reported
UACR, % change-22.4% vs -1.8%−20.6 vs placebo10 mg · wk 24 · n 140NCT02547935
9 other results
  • -39.1% vs -1.8% 10 mg + 2.5 mg · wk 24 · n 151 · Phase 2/3 · primary NCT02547935
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · primary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
—Not reported
eGFR slope—Not posted · NCT05998837—Not reported
Haemoglobin, change—Not posted · NCT05998837—Not reported

Kidney composite outcome

Dapagliflozin
6.6% vs 11.3%−4.7 vs placebon 2152NCT03036150
janagliflozin
—Not reported

UACR, % change

Dapagliflozin
-22.4% vs -1.8%−20.6 vs placebo10 mg · wk 24 · n 140NCT02547935
9 other results
  • -39.1% vs -1.8% 10 mg + 2.5 mg · wk 24 · n 151 · Phase 2/3 · primary NCT02547935
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · primary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
janagliflozin
—Not reported

eGFR slope

Dapagliflozin
—Not posted · NCT05998837
janagliflozin
—Not reported

Haemoglobin, change

Dapagliflozin
—Not posted · NCT05998837
janagliflozin
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

janagliflozin: no structured comparison results are available for Chronic Kidney Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dapagliflozin: 4 of 4 rows · janagliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapagliflozin
Dropout rate
—10 mga
NCT03036150 · Phase 3
show 10 more results
0.5%Dapagliflozin
NCT03036150 · Phase 3
5.5%10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
3.2%10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
17.1%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
25%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
24.2%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
5.7%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
20.7%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
9.9%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—10 mga
NCT03036150 · Phase 3
show 10 more results
—Dapagliflozin
NCT03036150 · Phase 3
—10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
—10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
2.9%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
8.3%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
12.1%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
0%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
3.9%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
2.2%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
Serious AEs
29.5%10 mga
NCT03036150 · Phase 3
show 10 more results
—Dapagliflozin
NCT03036150 · Phase 3
8.3%10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
7.9%10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
12.1%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
5.9%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
9.7%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
3%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
5.6%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
2.2%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
1.9%10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
10 mga
nasopharyngitis 4.3% (placebo 3.8%)
urinary tract infection 3.6% (placebo 3.7%)
hypoglycaemia 3.4% (placebo 3.3%)
NCT03036150 · Phase 3
show 9 more results
10 mg
nasopharyngitis 6.9% (placebo 4.1%)
influenza 5.5% (placebo 1.4%)
NCT02547935 · Phase 2/3 · registry result, not featured evidence
10 mg + 2.5 mg
nasopharyngitis 6.6% (placebo 4.1%)
influenza 1.3% (placebo 1.4%)
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
10 mg
hyperkalaemia 9.1% (placebo 0%)
urinary tract infection 9.1% (placebo 0%)
fall 6.1% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence
150 mg + 10 mg
nasopharyngitis 8.8% (placebo 0%)
chronic kidney disease 5.9% (placebo 0%)
diarrhoea 5.9% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
50 mg + 10 mg
urinary tract infection bacterial 6.5% (placebo 0%)
chronic kidney disease 3.2% (placebo 0%)
hyperkalaemia 3.2% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
15 mg + 10 mg
chronic kidney disease 3% (placebo 0%)
colitis 0% (placebo 20%)
diabetes mellitus 0% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
1.5 mg
brain natriuretic peptide increased 5% (placebo 0.6%)
headache 4.5% (placebo 1.1%)
metabolic acidosis 3.9% (placebo 1.1%)
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
0.25 mg
headache 6.6% (placebo 1.1%)
hypertension 5.5% (placebo 0.6%)
metabolic acidosis 5.5% (placebo 1.1%)
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
10 mg
any adverse event 32.1% (placebo 25%)
NCT03190694 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapagliflozin

Time to Cardio-renal Composite Endpoint 9.2% (n=2152) vs 14.5% (n=2152) placebo
event count · % of participants
NCT03036150 · Phase 3 · converted to % from 197 Participants as posted
Time to Composite Renal Endpoint 6.6% (n=2152) vs 11.3% (n=2152) placebo
event count · % of participants
NCT03036150 · Phase 3 · converted to % from 142 Participants as posted
Time to CV Death or HF Hospitalization 4.6% (n=2152) vs 6.4% (n=2152) placebo
event count · % of participants
NCT03036150 · Phase 3 · converted to % from 100 Participants as posted
Overall Survival 4.7% vs 6.8% placebo
time to event · count
NCT03036150 · Phase 3
HbA1c -0.43% (n=140) vs -0.27% (n=145) placebo @ 24wk10 mg
absolute change · percentage points
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-0.85% (n=151) vs -0.27% (n=145) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
UACR -22.4% (n=140) vs -1.8% (n=144) placebo @ 24wk10 mg
percent change · % of baseline
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 9 more results
-34.318% (n=28) vs 230.32% (n=3) placebo @ 12wk10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
-34.318% (n=28) vs 230.32% (n=7) placebo @ 12wk10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
-58.047% (n=25) vs 230.32% (n=3) placebo @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-58.047% (n=25) vs 230.32% (n=7) placebo @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-42.085% (n=23) vs 230.32% (n=3) placebo @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-42.085% (n=23) vs 230.32% (n=7) placebo @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-56.391% (n=32) vs 230.32% (n=3) placebo @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-56.391% (n=32) vs 230.32% (n=7) placebo @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-39.1% (n=151) vs -1.8% (n=144) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Weight -1.48% (n=144) vs -0.61% (n=148) placebo @ 24wk10 mg
percent change · % of baseline
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-0.65% (n=152) vs -0.61% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Fasting Plasma Glucose Change mg/dL -13.1 vs -11.2 placebo mg @ 24wk10 mg
absolute change · mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-17.2 vs -11.2 placebo mg @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
UACR 30 45% (n=144) vs 31.3% (n=148) placebo @ 24wk10 mg
responder rate · % of participants
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
57% (n=152) vs 31.3% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
HbA1c Less Than 7 15% (n=144) vs 10.3% (n=148) placebo @ 24wk10 mg
absolute value · percentage points
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
35.1% (n=152) vs 10.3% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Seated SBP -6.9 vs -4.1 placebo mmHg @ 24wk10 mg
absolute change · mmHg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-8.8 vs -4.1 placebo mmHg @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
eGFR -3.498 vs 6.88 placebo mL @ 12wk10 mg
absolute change · mL
NCT04595370 · Phase 2 · registry result, not featured evidence
show 3 more results
-5.307 vs 6.88 placebo mL @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-1.16 vs 6.88 placebo mL @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-1.432 vs 6.88 placebo mL @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapagliflozin's landscape · janagliflozin's landscape